First Patient Dosed in Syros’ Phase 1 Trial for Ovarian, Other Solid Tumors

First Patient Dosed in Syros’ Phase 1 Trial for Ovarian, Other Solid Tumors
The first patient has been dosed in a Phase 1 trial assessing Syros Pharmaceuticals‘ investigative therapy SY-1365 in patients with advanced solid tumors, the company announced. The trial will particularly enroll participants with cancers that are highly dependent on transcription processes to thrive, including ovarian cancer, triple-negative breast cancer, and small cell lung cancer. “SY-1365

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *